Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1851 | IIBR-100 high-dose (prime) Wiki | 1.00 |
| drug1853 | IIBR-100 medium dose (prime) Wiki | 1.00 |
| drug1854 | IIBR-100, low dose (prime) Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.
Description: At the end of week 4, the average visual analogue scale (VAS) score of main clinical symptoms in the past 1 week changed from baseline. The VAS score ranges from 0 to 100 point and the higher scores mean worse symptoms (The main clinical symptoms including: Cough /chest tightness/shortness of breath after exercise/asthenia).
Measure: The change of the average VAS score from baseline to week 4 Time: week 4Description: At the end of week 2, week 4 and week 8, the average VAS score of main clinical symptoms in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 2, and week 8 Time: week 2 and week 8Description: At the end of week 2, week 4 and week 8, the severity VAS score of main clinical symptoms in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the severity VAS score from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average insomnia VAS score in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average insomnia VAS score from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average VAS score of sweating, mental fatigue, anorexia and nervousness in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average times of diarrhea and complete spontaneous bowel movement in the past 1 week changed from baseline.
Measure: The change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the proportion of patients whose average and severity VAS scores of main clinical symptoms (except diarrhea and constipation) in the past 1 week changed from baseline decreased 50% and 75%. VAS score measure is as same as the primary outcome.
Measure: The proportion of patients with 50%/75% improvement of clinical symptoms to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the walking distance of six-minute-walking test changed from baseline.
Measure: The change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the lowest oxygen saturation of six-minute-walking test changed from baseline.
Measure: The change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2 and week 4, the proportion of patients in recovery of pulmonary function in all participants.
Measure: The proportion of patients in recovery of pulmonary function on week 2 and week 4 Time: week 2 and week 4Description: Lung CT shows complete absorption of inflammation.
Measure: The proportion of patients whose lung CT return to normal on week 4 Time: week 4Description: At the end of week 4 and week 8, the WHO Quality of Life-BREF (WHO QOL-BREF) score changed from baseline. The higher scores mean better outcome.
Measure: The change of the WHO QOL-BREF score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4 and week 8, the Self-Rating Anxiety Scale (SAS) score changed from baseline. The higher scores mean worse outcome.
Measure: The change of the SAS score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4 and week 8, the Self-Rating Depression Scale (SDS) score changed from baseline.The higher scores mean worse outcome.
Measure: The change of the SDS score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4, the blood C-reactive protein (CRP) value changed from baseline.
Measure: The change of the blood CRP value from baseline to week 4 Time: week 4Description: At the end of week 4, the blood lymphocyte count (LYMPH#) changed from baseline.
Measure: The change of the blood LYMPH# value from baseline to week 4 Time: week 4Description: At the end of week 4, the percentage of blood neutrophils (NEUT%) value changed from baseline.
Measure: The change of the blood NEUT% value from baseline to week 4 Time: week 4Description: Divide the patients into two subgroups (the non-elderly ≤ 40 years old; the elderly > 40 years old ) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the two age groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different age groups. Time: week 4Description: Divide the patients into two subgroups (man; woman) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the two gender groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different gender groups. Time: week 4Description: Divide the patients into four subgroups ( mild type；common type；severe type；critical type) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the four clinical classification groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different clinical classification of COVID-19. Time: week 4Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports